Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:17 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 3,915 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Not listed No phase listed Observational

Digitally Captured Activity Data and PROs to Monitor Physical Function in Prostate Cancer Patients

NCT04575402
View directory record Official record
Conditions
Prostate Cancer
Interventions
Wearable Activity Monitor
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Nov 2, 2026, 5:17 PM EST
No Longer Available No phase listed Expanded access

68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)

NCT04854369
View directory record Official record
Conditions
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Interventions
68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Nov 2, 2026, 5:17 PM EST
Withdrawn Phase 2 Interventional

A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

NCT02906605
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
JNJ-809, Apalutamide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Nov 2, 2026, 5:17 PM EST
Recruiting Not applicable Interventional

RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer

NCT06856694
View directory record Official record
Conditions
Prostate Cancer, Shared Decision Making, Risk Communication
Interventions
NLP+AI Report
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 2 Interventional

A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)

NCT00028353
View directory record Official record
Conditions
Prostatic Intraepithelial Neoplasia
Interventions
GTX-006 (Acapodene)
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Aventura, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Nov 2, 2026, 5:17 PM EST
Recruiting Phase 2 Interventional

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

NCT06392295
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
Interventions
Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy, Androgen Receptor Signaling Inhibitor
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1Phase 2 Interventional

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

NCT04060394
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Phase I and Phase II: LAE001/prednisone + afuresertib
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 1 Interventional Results available

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

NCT04702737
View directory record Official record
Conditions
Neuroendocrine Prostate Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Nov 2, 2026, 5:17 PM EST
Terminated Phase 2 Interventional Results available

Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

NCT01354951
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
New Hyde Park, New York • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 3 Interventional Results available

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

NCT00699751
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer, Bone Metastases
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Best standard of care (BSoC)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Los Angeles, California • Roseville, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Completed Early Phase 1 Interventional Results available

Intensity Modulated Radiation Therapy for Prostate Cancer

NCT00214422
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 3 Interventional Results available

A Study of Leuprolide to Treat Prostate Cancer

NCT00626431
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate - Formulation A, Leuprolide acetate - Formulation B
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older · Male only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Nov 2, 2026, 5:17 PM EST
Terminated No phase listed Observational

Salvage Cryotherapy in Recurrent Prostate Cancer

NCT00824928
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Cryoablation / Cryotherapy
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
17
States / cities
Loma Linda, California • Sacremento, California • Ventura, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Nov 2, 2026, 5:17 PM EST
Not listed Phase 1Phase 2 Interventional

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

NCT01436214
View directory record Official record
Conditions
Prostate Cancer
Interventions
APC-100
Drug
Lead sponsor
Adamis Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Detroit, Michigan • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Nov 2, 2026, 5:17 PM EST
Not listed Phase 3 Interventional

I-125 Versus Pd-103 for Medium Risk Prostate Cancer

NCT00486499
View directory record Official record
Conditions
Prostate Cancer
Interventions
I-125 versus Pd-103 radioactive seed insertion
Procedure
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
40 Years to 90 Years · Male only
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2007 · Synced Nov 2, 2026, 5:17 PM EST
Recruiting No phase listed Observational

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

NCT07096999
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Completed No phase listed Observational Results available

An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres

NCT04272216
View directory record Official record
Conditions
Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
Interventions
Treatment with HydroPearl via radial access
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 4 Interventional Results available

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

NCT00363311
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
Dutasteride, Matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
58
States / cities
Little Rock, Arkansas • Beverly Hills, California • Laguna Hills, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Nov 2, 2026, 5:17 PM EST
Terminated No phase listed Observational

Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy

NCT04234399
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Fluciclovine PET/CT using a digital PET/CT
Diagnostic Test
Lead sponsor
University of Vermont
Other
Eligibility
40 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Prostate Cancer Screening: Fostering Informed Decisions

NCT00196807
View directory record Official record
Conditions
Prostate Cancer
Interventions
patient decision aid (print-based)
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
543 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Nov 2, 2026, 5:17 PM EST
Completed Phase 2 Interventional Results available

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

NCT03093428
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Nov 2, 2026, 5:17 PM EST
Recruiting Phase 2 Interventional

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

NCT06039371
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Etoposide, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate, Radioconjugate, Dual X-ray Absorptiometry, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 2, 2026, 5:17 PM EST
Completed Not applicable Interventional

Does Protein Restriction Inhibit Prostrate Cancer Growth

NCT01692587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Protein restrictive diet
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Nov 2, 2026, 5:17 PM EST
Completed Not applicable Interventional

Pillars4Life Trial

NCT02465892
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer, Pancreatic Cancer, Liver Cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Pillars4Life
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 2, 2026, 5:17 PM EST